Jianfeng Group announced that its subsidiary Jianfeng Beika has received the Chemical API Marketing Application Approval Notice for methyldopa from the National Medical Products Administration, valid until August 24, 2031. Methyldopa was developed by Merck Sharp and Dohme and approved for marketing in the United States in 1962. It is the world's first-generation centrally acting antihypertensive drug and a classic first-choice medication for hypertension during pregnancy. Jianfeng Beika submitted its technical review application in March 2025, with cumulative research and development investment of approximately 3.36 million yuan. The company stated that this approval indicates the API meets relevant national technical review standards and can be sold in the domestic market, helping to expand the subsidiary's business areas.
Zhejiang Jianfeng Group Co LtdSubsidiary Jianfeng Beika received NMPA marketing approval for methyldopa API, allowing domestic sales and expanding its business areas.
